

Elisa Menegatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1364926/publications.pdf>

Version: 2024-02-01

52
papers

1,049
citations

331259

21
h-index

454577

30
g-index

52
all docs

52
docs citations

52
times ranked

1700
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. <i>Immunologic Research</i> , 2021, 69, 372-377.	1.3	4
2	Variants in <i>ATP6VOA1</i> cause progressive myoclonus epilepsy and developmental and epileptic encephalopathy. <i>Brain Communications</i> , 2021, 3, fcab245.	1.5	10
3	Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. <i>Frontiers in Immunology</i> , 2021, 12, 769785.	2.2	6
4	Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. <i>Autoimmunity Reviews</i> , 2020, 19, 102449.	2.5	10
5	Treatment of antiphospholipid syndrome. <i>Clinical Immunology</i> , 2020, 221, 108597.	1.4	11
6	Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2020, 19, 102641.	2.5	13
7	Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network. <i>Italian Journal of Pediatrics</i> , 2020, 46, 130.	1.0	14
8	The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2921-2928.	1.9	7
9	Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9551.	1.8	11
10	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102488.	2.5	5
11	Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. <i>Rheumatology</i> , 2019, 58, 1870-1872.	0.9	1
12	Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. <i>Frontiers in Immunology</i> , 2019, 10, 376.	2.2	34
13	Spontaneous remission in a Diamond-Blackfan anaemia patient due to a revertant uniparental disomy ablating a <i>de novo</i> RPS19 mutation. <i>British Journal of Haematology</i> , 2019, 185, 994-998.	1.2	24
14	SAT-346 POR Rs2286822 Polymorphism Is Associated with Clinical Features in Patients with Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
15	Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. <i>Lupus</i> , 2018, 27, 1393-1394.	0.8	7
16	Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. <i>Oncotarget</i> , 2018, 9, 28799-28804.	0.8	23
17	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. <i>Autoimmunity Reviews</i> , 2018, 17, 1138-1149.	2.5	88
18	The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female. <i>Gynecological Endocrinology</i> , 2017, 33, 918-922.	0.7	1

#	ARTICLE	IF	CITATIONS
19	High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. <i>American Journal of Nephrology</i> , 2017, 46, 108-113.	1.4	24
20	Immunological Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 497-509.	0.8	2
21	Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort. <i>BMJ Open</i> , 2017, 7, e015243.	0.8	26
22	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 55-69.	0.5	1
23	The 4 plus 2 rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. <i>Oncotarget</i> , 2017, 8, 52072-52077.	0.8	15
24	The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. <i>Oncotarget</i> , 2017, 8, 41764-41777.	0.8	28
25	Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. <i>American Journal of Nephrology</i> , 2016, 43, 251-260.	1.4	38
26	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. <i>Clinical and Molecular Allergy</i> , 2016, 14, 6.	0.8	37
27	New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. <i>Autoimmunity Reviews</i> , 2016, 15, 529-538.	2.5	64
28	Immunogenetics of complement in mixed cryoglobulinaemia. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S12-5.	0.4	6
29	Possible role for interleukins as biomarkers for mortality and recurrence in oral cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 262-266.	0.7	22
30	A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: Clinical response compared to literature and immunological re-assessment. <i>Autoimmunity Reviews</i> , 2015, 14, 1123-1130.	2.5	52
31	Piedmont and Aosta Valley inter-regional network in the context of the Italian National Network for rare diseases. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s617-20.	0.3	4
32	Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2013, 757, 104-113.	0.9	10
33	Lab-on-a-chip: Emerging analytical platforms for immune-mediated diseases. <i>Autoimmunity Reviews</i> , 2013, 12, 814-820.	2.5	19
34	Common variable immunodeficiency: Crossroads between infections, inflammation and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 796-801.	2.5	49
35	8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. <i>Inflammation Research</i> , 2012, 61, 809-816.	1.6	27
36	Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3987-3992.	0.4	61

#	ARTICLE	IF	CITATIONS
37	Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis. <i>American Journal of Nephrology</i> , 2011, 34, 175-180.	1.4	35
38	PPAR β ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1347-1357.	1.6	23
39	4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 818-826.	1.9	27
40	Genetic Factors Associated with Rheumatoid Arthritis and Systemic Vasculitis: Evaluation of a Panel of Polymorphisms. <i>Disease Markers</i> , 2009, 27, 217-223.	0.6	18
41	Rituximab in cryoglobulinemic peripheral neuropathy. <i>Journal of Neurology</i> , 2009, 256, 1076-1082.	1.8	54
42	Genetic factors associated with rheumatoid arthritis and systemic vasculitis: Evaluation of a panel of polymorphisms. <i>Disease Markers</i> , 2009, 27, 217-23.	0.6	11
43	Relationship between cryoglobulinemia-associated nephritis and HCV infection. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 515-524.	1.3	1
44	4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. <i>Free Radical Biology and Medicine</i> , 2006, 40, 1578-1591.	1.3	38
45	Absence of NF- κ B Activation by a New Polystyrene-Type Adsorbent Designed for Hemoperfusion. <i>Blood Purification</i> , 2005, 23, 91-98.	0.9	32
46	Somatic Mosaicism and Variable Expressivity in Diamond Blackfan Anemia (DBA): A Large Deletion Involving the 19q13 Locus in a Patient with Transient Anemia.. <i>Blood</i> , 2005, 106, 3550-3550.	0.6	0
47	Cytokine Release Pathway in Mononuclear Cells Stimulated in vitro by Dialysis Membranes. <i>American Journal of Nephrology</i> , 2002, 22, 509-514.	1.4	5
48	Polymorphism of the Uteroglobin Gene in Systemic Lupus Erythematosus and IgA Nephropathy. <i>Laboratory Investigation</i> , 2002, 82, 543-546.	1.7	23
49	It is the goal of this section to publish material that provides information regarding specific issues, aspects of artificial organ application, approach, philosophy, suggestions, and/or thoughts for the future. 5 α -Lipoxygenase Gene Expression in Hemodialysis. <i>Artificial Organs</i> , 1998, 22, 140-142.	1.0	5
50	Intradialytic Cytokine Gene Expression. <i>Blood Purification</i> , 1998, 16, 30-36.	0.9	12
51	Effects of ANCA-Positive Sera on the Generation of Oxygen Free Radicals by Neutrophils1. <i>Contributions To Nephrology</i> , 1992, 99, 108-113.	1.1	0
52	Classic and Perinuclear Anti-Neutrophil Cytoplasm Antibodies and Antimyeloperoxidase Antibodies in Rapidly Progressive Glomerulonephritis. <i>American Journal of Nephrology</i> , 1991, 11, 318-324.	1.4	11